EyeGate Pharma announces positive results for phase 2 study of drug, delivery system for dry eye

WALTHAM, Mass. — A phase 2 trial has demonstrated the ability of EyeGate Pharma's proprietary corticosteroid solution and ocular drug delivery system to improve the signs and symptoms of dry eye syndrome, according to a press release from the company.

The single-center, randomized, double-masked, placebo-controlled study evaluated the safety and efficacy of EGP-437 when administered by the EyeGate II Delivery System at two dose levels twice over a 3-week period among 105 patients with dry eye syndrome.

Using Ora's Controlled Adverse Environment system to simulate the acute environmental challenges of dry eye syndrome, the investigators found that EGP-437 significantly improved the signs and symptoms of disease. EGP-437 also improved signs and symptoms when studied as a treatment and preventative in conjunction with the controlled adverse environment, according to the release.

"We are excited about the prospect that EGP-437 may prove to be a useful therapy for the moderate to severe dry eye patients that are currently underserved by available treatments," Stephen From, president and chief executive officer of EyeGate Pharma, said in the release. "This non-invasive drug delivery technology has the potential to help patients with a broad range of eye diseases, and we are encouraged by these results."

EyeGate Pharma has already submitted an abstract of study results to an undisclosed upcoming scientific conference.